Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €55.64 EUR
Change Today +0.356 / 0.64%
Volume 0.0
As of 1:36 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

ipsen (I7G) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - €57.67
52 Week Low
08/22/14 - €31.53
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IPSEN (I7G)

Related News

No related news articles were found.

ipsen (I7G) Related Businessweek News

View More BusinessWeek News

ipsen (I7G) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates through two segments, Primary Care and Specialty Care. The company offers drugs in uro-oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and cardiovascular areas. Its products include Decapeptyl, a peptide formulation for injection for the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline, which is used primarily in the treatment of acromegaly and neuroendocrine tumors. The company also provides NutropinAq, a liquid formulation for use in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it offers Smecta, a natural clay-based drug for use in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan, an oral formulation, which is used for the treatment of age-related cognitive disorders. Further, the company provides Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl products. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

4,304 Employees
Last Reported Date: 03/30/15
Founded in 1929

ipsen (I7G) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.8M
Deputy Chief Executive Officer
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

ipsen (I7G) Key Developments

Ipsen S.A. - Analyst/Investor Day

To provide an update on 2020 strategy and outlook

Ipsen S.A. Approves Dividend, Payable on 2 June 2015

Ipsen S.A. announced that its shareholders have approved the distribution of €0.85 dividend per share to be paid on 2 June 2015 (ex-dividend date 29 May 2015), at its combined shareholders’ meeting held on 27 May 2015.

Ipsen S.A. Proposes Gross Dividend, Payable on June 2, 2015

The board of directors of Ipsen S.A. proposed to the general shareholders' meeting to distribute a gross dividend of €0.85 for each share and subsequently to appropriate 2014 year's profit. The ex-dividend date is set on May 29, 2015 and the dividend will be paid on June 2, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I7G:GR €55.64 EUR +0.356

I7G Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥2,598 JPY -45.50
H Lundbeck A/S kr156.50 DKK -2.50
View Industry Companies

Industry Analysis


Industry Average

Valuation I7G Industry Range
Price/Earnings 27.2x
Price/Sales 3.1x
Price/Book 3.9x
Price/Cash Flow 27.6x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at